MarketFriction

Fulford (India) Ltd

BSE 506803 · Pharmaceuticals
Market cap₹Cr.
Not trading

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Mar 2013Jun 2013Sep 2013Dec 2013Mar 2014Jun 2014Sep 2014Dec 2014Mar 2015
Revenue from operations46.6561.4859.6955.8345.9957.0764.3949.1446.47
Operating costs54.7860.0554.9153.4251.1255.7256.8460.3352.82
EBITDA-8.131.434.782.41-5.131.357.55-11.19-6.35
EBITDA margin %-17.43%2.33%8.01%4.32%-11.15%2.37%11.73%-22.77%-13.66%
Depreciation & amortisation0.390.330.280.270.250.210.220.120.05
Finance costs0.010.770.000.040.130.010.010.24-0.07
Non-operating income2.582.452.252.682.582.292.882.176.88
Pre-tax profit-5.952.786.754.78-2.933.4210.20-9.380.55
Effective tax rate %-31.93%33.81%35.26%27.20%-60.07%33.92%34.22%-31.34%140.00%
Profit after tax-4.051.844.373.48-1.172.266.71-6.44-0.22
Earnings per share (Rs)-10.384.7211.218.92-3.005.7917.21-16.51-0.56
Dec 2009Dec 2010Dec 2011Dec 2012Mar 2014 15mMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue from operations18419021321326523015514212210010970
Operating costs16717921822827023918211999797944
EBITDA1711-5-15-5-9-272322213026
EBITDA margin %9%6%-2.3%-7%-1.8%-3.8%-17%16%18%21%28%38%
Depreciation & amortisation122221000000
Finance costs000010000000
Non-operating income6891013146771995
Pre-tax profit22173-755-212929393931
Effective tax rate %39%31%32%-31%18%52%-33%39%39%30%27%41%
Profit after tax13122-542-141818282818
Earnings per share (Rs)34.5130.924.72-12.7911.465.92-36.2645.4645.7271.2672.6746.36
Paid out as dividend %13%15%74%-8%17%25%0%2%2%5%1%654%
10 Years5 Years3 YearsTTM1 YearLast Year
Revenue CAGR-10%-15%-17%-36%
Profit CAGR4%27%1%-36%
Share price CAGR%%%%
Average return on equity6%13%13%11%
Dec 2009Dec 2010Dec 2011Dec 2012Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Net block (property, plant)664311110000
Capital work in progress000000000000
Investments1500000000000
Current & other assets156187212198206190177204211226255150
Total assets177192216201208191179205212227255150
Share capital444444444444
Reserves & surplus136146146141144146132150167194222111
Total debt000000000000
Other liabilities & provisions374266565941435241282935
Equity + liabilities177192216201208191179205212227255150
Dec 2009Dec 2010Dec 2011Dec 2012Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Operating cash flow-5611-279-7661777434
Investing cash flow118881013-3142-43-3704
Free cash flow (after capex)-9411-279-7651787434
Financing cash flow-1-2-2-2-1-1-1-0-0-1-1-129
Net change in cash-52217-2018-64-2658-36373-92
Cash conversion (OCF / EBITDA) %37%143%-329%156%-376%764%-68%156%97%112%81%163%
Dec 2009Dec 2010Dec 2011Dec 2012Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Return on capital employed %17%12%2%-5%4%3%-15%20%18%22%18%18%
Receivable days29221611432212610125934
Inventory days1421251451389717511816711711921121
Payable days1121271601231266892220217155193222
Cash cycle (days)5920126-2513947-27-90-25-113-67
Working capital days5052-217-14759-13-20724-32

Fundamentals

Market value₹ Cr.
Last price₹ 2,362
Book value / share₹ 294
Return on capital18.1 %
Return on equity10.6 %
Dividend yield0.00 %
Face value₹ 10.0
Revenue CAGR (TTM)-36%
Profit CAGR (TTM)-36%
Standalone figures.
Valuation
P/E, 3-year average38.28x
P/B, 3-year average5.49x
P/E, 5-year average43.69x
P/B, 5-year average5.58x
Profitability
Operating margin (excl. other income)37.50%
Operating margin (incl. other income)43.93%
EBITDA margin1.15%
Pre-tax margin0.60%
Net profit margin0.63%
Net margin, latest quarter-13.11%
ROE10.61%
ROCE18.06%
ROA8.94%
ROE, 3-year average13.02%
ROCE, 3-year average19.34%
ROA, 3-year average11.13%
ROE, 5-year average12.46%
ROCE, 5-year average19.19%
ROA, 5-year average10.23%
ROIC (approx.)1.46%
Tax rate41.22%
Other income / net worth3.93%
Growth
Sales growth (latest year)-35.94%
Profit growth (latest year)-36.20%
Sales CAGR, 3 years-16.77%
Sales CAGR, 5 years-14.71%
Profit CAGR, 3 years0.47%
Sales growth QoQ-23.68%
Profit growth QoQ-195.98%
Sales growth YoY (latest quarter)-11.98%
Profit growth YoY (latest quarter)-285.06%
Per share
EPS (TTM)Rs 3.61
EPS (latest year)Rs 48.01
EPS (latest quarter)Rs -17.10
EPS, 3-year averageRs 63.98
EPS, 5-year averageRs 56.62
Book value per shareRs 304.62
Sales per shareRs 575.12
Cash flow per shareRs 89.14
Dividend per share (latest year)Rs 313.78
Dividend per share, 3-year averageRs 106.23
Dividend per share, 5-year averageRs 64.14
Dividends
Dividend payout653.60%
Dividend payout, 3-year average220.15%
Dividend payout, 5-year average132.97%
Efficiency
Asset turnover0.47x
Fixed asset turnover7006.00x
Inventory turnover3.08x
Inventory days118 days
Debtor days34 days
Debtors turnover10.60x
Leverage
Cash and bankRs 46 Cr
Net debtRs -46 Cr
Net debt / EBITDA-18.46x
Interest coverage4.36x
Owners' fund to total sources76.64%
Cash flow
Operating cash flow (latest year)Rs 34 Cr
Investing cash flow (latest year)Rs 4 Cr
Financing cash flow (latest year)Rs -129 Cr
Net change in cash (latest year)Rs -92 Cr
Sales to cash flow2.09x
Statement figures
Net sales (TTM)Rs 217 Cr
Net sales (latest year)Rs 70 Cr
Sales (latest quarter)Rs 49 Cr
Operating profit excl. other income (latest year)Rs 26 Cr
Operating profit (latest quarter)Rs -11 Cr
Other income (TTM)Rs 10 Cr
EBITDA (TTM)Rs 2 Cr
PBDT (TTM)Rs 2 Cr
Profit before tax (TTM)Rs 1 Cr
Tax (latest year)Rs 13 Cr
Net profit (TTM)Rs 1 Cr
Net profit (latest year)Rs 18 Cr
Net profit (latest quarter)Rs -6 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 27 Cr
Total expenditure (latest year)Rs 44 Cr
Total income (latest year)Rs 75 Cr
Share capitalRs 4 Cr
ReservesRs 111 Cr
Shareholders' fundsRs 115 Cr
Total assetsRs 150 Cr
Net blockRs 0 Cr
ReceivablesRs 7 Cr
InventoryRs 9 Cr
Other liabilitiesRs 35 Cr
Shares outstanding (crore)0.38
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.

Red flags

F-score 8 of 8
lookInventory outrunning sales Inventory grew 310% vs sales -36% in 2021
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Mar 2015
Sales ₹46 Cr +1.0% vs Mar 2014. Net loss ₹0 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Fulford (India) Ltd?

Fulford (India) Ltd (506803) has a market capitalisation of Rs Cr. at the close.

What were Fulford (India) Ltd's latest quarterly results?

In the Mar 2015 quarter, Fulford (India) Ltd sales was Rs 46 Cr (+1.0% vs Mar 2014) with a net loss of Rs 0 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03